Relmada Therapeutics, Inc

Relmada Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to improving the standard of care for central nervous system (CNS) disorders, particularly major depressive disorder (MDD). Their primary focus is on developing innovative treatments that target impaired neural plasticity, a process that involves the brain reorganizing its connections and reshaping its structure. Relmada believes that restoring neural plasticity in areas related to MDD can lead to rapid and lasting remission of depressive episodes.

Their lead program, REL-1017 (esmethadone), is an NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels associated with MDD. REL-1017 is currently in Phase 3 development for the treatment of MDD and has demonstrated potential efficacy and a favorable safety profile in clinical trials. Relmada is also exploring other potential therapies based on their understanding of neural plasticity, including a novel Neuroplastogen program and a modified release psilocybin formulation for metabolic disorders.

Relmada Therapeutics is dedicated to reshaping the standard of care for central nervous system disorders, particularly in the realm of mental health. Their primary focus is on developing revolutionary treatments for major depressive disorder (MDD) through the advancement of their Phase 3 program for REL-1017, a novel NMDA receptor channel blocker that targets hyperactive channels associated with MDD while maintaining physiological glutamatergic neurotransmission. Relmada seeks to provide safe, efficacious, and rapid-acting treatment options for patients suffering from MDD and other CNS disorders.

Relmada Therapeutics fosters a culture of innovation and collaboration, with a strong focus on developing transformative medicines for those living with central nervous system (CNS) disorders. The company emphasizes scientific rigor and leadership, attracting employees with extensive CNS expertise and experience from leading biopharmaceutical companies. This blend of scientific expertise and collaborative spirit is reflected in the company's commitment to improving the standard of care for CNS treatments, with a particular focus on major depressive disorder (MDD).

Relmada Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace, believing that a broad range of perspectives and experiences leads to better scientific innovation. The company actively seeks to recruit and retain employees from diverse backgrounds, and their Board of Directors reflects this commitment. The company also prioritizes fostering a culture of belonging where all employees feel respected, valued, and supported, regardless of their background.